Olof Zachrisson

Stockholm, AB 12944, Sweden

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Antibody Titres to Strangvac® Antigens Correlate with Protection and Duration of Immunity Against Experimental Infection with Streptococcus equi Subspecies equi.

Antibody Titres to Strangvac® Antigens Correlate with Protection and Duration of Immunity Against Experimental Infection with Streptococcus equi Subspecies equi.

Journal: Vaccines
Published: May 12, 2026

Exidavnemab binds to aggregated α-synuclein in human brains affected by α-synucleinopathies.

Exidavnemab binds to aggregated α-synuclein in human brains affected by α-synucleinopathies.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: June 30, 2025

Exidavnemab binds to aggregated α-synuclein in human brains affected by α-synucleinopathies.

Exidavnemab binds to aggregated α-synuclein in human brains affected by α-synucleinopathies.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: June 30, 2025

The Swedish bipolar collection (SWEBIC).

The Swedish bipolar collection (SWEBIC).

Journal: International journal of bipolar disorders
Published: February 25, 2025

A brain-penetrant bispecific antibody lowers oligomeric alpha-synuclein and activates microglia in a mouse model of alpha-synuclein pathology.

A brain-penetrant bispecific antibody lowers oligomeric alpha-synuclein and activates microglia in a mouse model of alpha-synuclein pathology.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: August 27, 2024

Disease modifying effects of the amyloid-beta protofibril-selective antibody mAb158 in aged Tg2576 transgenic mice.

Disease modifying effects of the amyloid-beta protofibril-selective antibody mAb158 in aged Tg2576 transgenic mice.

Journal: Molecular and cellular neurosciences
Published: April 04, 2024

Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains.

Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains.

Journal: Molecular and cellular neurosciences
Published: March 28, 2024

Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities.

Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities.

Journal: Scientific reports
Published: December 22, 2023

ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease.

ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease.

Journal: Neurobiology of disease
Published: July 09, 2021

In vivo imaging of alpha-synuclein with antibody-based PET.

In vivo imaging of alpha-synuclein with antibody-based PET.

Journal: Neuropharmacology
Published: July 04, 2021

Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease.

Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease.

Journal: Molecular and cellular neurosciences
Published: March 02, 2021

Open-label study with the monoamine stabilizer (-)-OSU6162 in myalgic encephalomyelitis/chronic fatigue syndrome.

Open-label study with the monoamine stabilizer (-)-OSU6162 in myalgic encephalomyelitis/chronic fatigue syndrome.

Journal: Brain and behavior
Published: April 23, 2020
Showing 1-12 of 20

Last Updated: 09/26/2026